| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 01/18/2006 | EP1501505B1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases |
| 01/18/2006 | EP1470138B1 Mmp inhibitors |
| 01/18/2006 | EP1404672B1 Tyrosine kinase inhibitors |
| 01/18/2006 | EP1232183B1 Peptides having antiangiogenic activity |
| 01/18/2006 | EP1220852B1 Substituted diazepans |
| 01/18/2006 | EP1214064A4 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 01/18/2006 | EP1169475B1 Diagnosis of a person's risk for developing diabetic retinopathy |
| 01/18/2006 | EP0735895B1 A method for preventing or controlling cataract |
| 01/18/2006 | CN1721412A 7-oxo pyridopyrimidines |
| 01/18/2006 | CN1720960A Freeze dried powder injection with red sage root and notoginseng and its preparation process |
| 01/18/2006 | CN1237075C Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 01/18/2006 | CN1237062C Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/18/2006 | CN1236775C Compositions and methods for reducing ocular hypertension |
| 01/18/2006 | CN1236763C Use of an epoxy-sterodal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 01/17/2006 | US6987110 Such as 3-(1-(2-hydroxyethyl)-1H-indol-3-yl)-4-(1-(3-pyridinyl)-1H-indol-3-yl)-1H -pyrrole-2,5-dione |
| 01/17/2006 | US6987105 Prevent apoptosis; vision defects; central nervous system disorders; antiischemic agents; stroke therapy |
| 01/17/2006 | US6987093 Single dose azithromycin |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6986763 Methods and compositions usable in cataract surgery |
| 01/17/2006 | CA2346171C Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid |
| 01/17/2006 | CA2334713C Therapeutic biaryl derivatives |
| 01/12/2006 | WO2006004757A2 Topical formulations for treating allergic diseases |
| 01/12/2006 | US20060009534 Preventing and/or treating cardiovascular disease and/or associated heart failure |
| 01/12/2006 | US20060009528 Cannabinoid receptor ligands |
| 01/12/2006 | US20060009525 Hydroxamic acids and acyl hydroxamines as NAALADase inhibitors |
| 01/12/2006 | US20060009503 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 01/12/2006 | US20060009497 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/12/2006 | US20060009495 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/12/2006 | US20060009439 Novel physiologically active substances |
| 01/12/2006 | US20060009415 Corneal epithelial migration promoter |
| 01/12/2006 | US20060009412 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
| 01/12/2006 | US20060009409 Double-stranded oligonucleotides |
| 01/12/2006 | US20060008900 Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene |
| 01/12/2006 | US20060008506 Method for preparing therapeutic ophthalmic articles using compressed fluids |
| 01/12/2006 | CA2572874A1 Urea derivative |
| 01/12/2006 | CA2572163A1 Pyrazole derivatives |
| 01/12/2006 | CA2569530A1 Thienopyrazole derivative having pde 7 inhibitory activity |
| 01/12/2006 | CA2569519A1 Topical formulations for treating allergic diseases |
| 01/11/2006 | EP1614697A1 Proteoglycan isolated from cartilaginous fish and process for producing the same |
| 01/11/2006 | EP1614688A1 Phenylazole compound, production process, and antioxidant drug |
| 01/11/2006 | EP1614684A1 Diamine derivative, production process, and antioxidizing drug |
| 01/11/2006 | EP1614683A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2006 | EP1614675A2 Amino acids with affinity for the alpha-2-delta protein |
| 01/11/2006 | EP1614428A1 Drug for preventing or treating angiogenic eye diseases |
| 01/11/2006 | EP1614421A2 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 01/11/2006 | EP1614419A1 Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| 01/11/2006 | EP1614418A1 use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia |
| 01/11/2006 | EP1613662A2 Novel method of obtaining chondroitin sulphuric acid and uses thereof |
| 01/11/2006 | EP1613621A1 Prostaglandin analogs as ep4 receptor agonists |
| 01/11/2006 | EP1613336A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils |
| 01/11/2006 | EP1613268A2 Methods for inhibition of angiogenesis |
| 01/11/2006 | EP1469887A4 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/11/2006 | EP1421082B1 piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 01/11/2006 | EP1366036B1 Compounds having activity as inhibitors of cytochrome p450rai |
| 01/11/2006 | EP1296670B1 Therapeutic combinations of fatty acids |
| 01/11/2006 | EP1294924B1 Competitive assay for identifying allosteric inhibitors |
| 01/11/2006 | EP0989805B1 Nucleic acid sequences for atp-binding cassette transporter |
| 01/11/2006 | EP0822822A4 Controlled release of miotic and mydriatic drugs in the anterior chamber |
| 01/11/2006 | CN1718224A Formation of medicine for treating cerebrovascular disease and ear diseases and preparing process |
| 01/11/2006 | CN1718199A Method for preparing ophthalmic solution for preventing senile macular degeneration by using microoganism culture |
| 01/11/2006 | CN1235890C Thizaolyl amide derivatives |
| 01/11/2006 | CN1235875C Substituted alpha hydroxy acid aspertate specific cysteine protease inhibitors and use thereof |
| 01/11/2006 | CN1235583C Benzimidazole derivatives as therapeutic agents |
| 01/11/2006 | CN1235582C Medicines for preventing and treating retina and cornea blood vessel diseases |
| 01/10/2006 | US6984655 Photodynamic therapy for selectively closing neovasa in eyeground tissue |
| 01/10/2006 | US6984651 Piperidine amides as modulators of chemokine receptor activity |
| 01/10/2006 | US6984649 Pyridine derivatives |
| 01/10/2006 | US6984648 TNF (tumor necrosis factor); for treating conditions such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease |
| 01/10/2006 | US6984641 Carboline derivatives as PDE5 inhibitors |
| 01/10/2006 | US6984629 Such as uridine 5'-diphosphoric acid for corneal epithelial migration promotion |
| 01/10/2006 | US6984628 Ophthalmic compositions comprising trefoil factor family peptides |
| 01/10/2006 | US6984397 Encapsulated pipecolic acid; immunosuppressants |
| 01/10/2006 | CA2425841C Angiostatic steroids |
| 01/10/2006 | CA2373395C Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| 01/10/2006 | CA2364178C N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| 01/10/2006 | CA2327758C (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/05/2006 | US20060004089 Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye |
| 01/05/2006 | US20060004084 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 01/05/2006 | US20060004051 Compounds |
| 01/05/2006 | US20060004033 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 01/05/2006 | US20060004029 Nitrogen-containing aromatic derivatives |
| 01/05/2006 | US20060004017 Quinazoline derivatives as angiogenesis inhibitors |
| 01/05/2006 | US20060004010 Ccr4 antagonist and medical use thereof |
| 01/05/2006 | US20060003996 Intralesional treatment of psoriasis |
| 01/05/2006 | US20060003987 Compounds and their uses |
| 01/05/2006 | US20060003915 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/05/2006 | US20060003410 Oxidoreductase for use in identifying modulators for prevention and treatment of diabetes, obesity, dyslipidemia, coronary heart, inflammatory and cancer disorders |
| 01/05/2006 | US20060003025 comprising from 1300 to 1500 mg/l of Na+, from 4500 to 6500 mg/l of K+, from 50 to 1300 mg/l of Mg++, from 20 to 350 mg/l of ca++, from 4000 to 6000 mg/l of Cl-, a pH of from 4-9, and an osmolality of from 150-700 mOsm/kg; for treating and cleaning the eye |
| 01/05/2006 | US20060002961 Immunogens; Streptococcus pneumoniae polysaccharide-protein conjugate/antigen, and adjuvant which induces (cytotoxic T) lymphocytes |
| 01/05/2006 | US20060002858 Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 01/04/2006 | EP1612272A2 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 01/04/2006 | EP1612266A2 Prostaglandin reductase |
| 01/04/2006 | EP1612215A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/04/2006 | EP1611891A2 Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| 01/04/2006 | EP1611887A2 Modulation of peroxisome proliferator-activated receptors |
| 01/04/2006 | EP1611883A1 Composition for ophthalmic use |
| 01/04/2006 | EP1611877A1 Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
| 01/04/2006 | EP1611248A1 Diagnostic method for glaucoma |
| 01/04/2006 | EP1611144A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| 01/04/2006 | EP1610780A2 Cyclic protein tyrosine kinase inhibitors |